Suchergebnisse - "Cantini, Fabrizio"

PubPharm (11)

1

Biosimilars for the treatment of psoriatic arthritis

enthalten in: Expert review of clinical immunology | 2019

von Cantini, F. | Benucci, M. | Li Gobbi, F. | +2

2

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

enthalten in: Seminars in arthritis and rheumatism | 2017

von Cantini, F. | Niccoli, L. | Nannini, C. | +10

3

Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy : an Italian nationwide survey

enthalten in: International journal of rheumatic diseases | 2016

von Cantini, F. | Lubrano, E. | Marchesoni, A. | +5

4

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

enthalten in: Rheumatology (Oxford, England) | 2015

von van der Heijde, D. | Breban, M. | Halter, D. | +9

5

Adalimumab, etanercept, infliximab, and the risk of tuberculosis : data from clinical trials, national registries, and postmarketing surveillance

enthalten in: The Journal of rheumatology. Supplement | 2014

von Cantini, F. | Niccoli, L. | Goletti, D.

6

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis : an approach to a personalized medicine

enthalten in: Arthritis care & research | 2013

von Gremese, E. | Carletto, A. | Padovan, M. | +14

7

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry : an appraisal of predictors

enthalten in: The Journal of rheumatology | 2012

von Iannone, F. | Gremese, E. | Atzeni, F. | +29

8

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis : a 4-year study

enthalten in: Rheumatology (Oxford, England) | 2010

von Spadaro, A. | Punzi, L. | Marchesoni, A. | +13

9

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years : long-term results from the ATLAS trial

enthalten in: Annals of the rheumatic diseases | 2009

von van der Heijde, D. | Schiff, M. | Sieper, J. | +43

10

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis : results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)

enthalten in: The Journal of rheumatology | 2008

von Revicki, D. | Luo, M. | Wordsworth, P. | +47

ErratumIn: J Rheumatol. 2011 Apr;38(4):788